Dabigatran in stroke prevention in atrial fibrillation
A practical guide for primary care
If we wanted to make things simple, all patients with atrial fibrillation (AF) would receive an oral anticoagulant to reduce their risk of stroke and other comorbidities. But historically this has been difficult because anticoagulants can cause bleeding. Decisions about oral anticoagulation in patients with AF are therefore complex, but novel oral anticoagulants offer the promise of more effective stroke prevention, as well as easier prescribing and more straightforward management.
Boehringer Ingelheim was involved in the outline development and medico-legal approval of this supplement and provided financial support for its publication. The views expressed in this publication are not necessarily those of the publisher or Boehringer Ingelheim. Full editorial control of the article rested with the authors and the journal. Full prescribing information is available at the end of the article.
For the latest prescribing information, please follow this link: http://www.pradaxa.co.uk/downloads/pi-spaf.pdf